Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Eli Lilly and Company's quarterly P/E stands at 30.7x, down 85.2% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 50.9% YoY to 20.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 89.85 | 30.72 | 30.98 | 67.48 | 39.55 | 207.00 | 69.01 | 78.42 | 60.22 | — | 63.03 | 60.46 | 44.83 |
| — | -85.2% | -55.1% | -14.0% | -34.3% | — | +9.5% | +29.7% | +34.3% | — | -18.3% | +68.9% | +17.5% | |
| P/S Ratio | 20.91 | 9.74 | 11.27 | 14.61 | 12.88 | 17.52 | 18.11 | 20.05 | 14.08 | 13.42 | 13.39 | 11.71 | 11.90 |
| — | -44.4% | -37.8% | -27.1% | -8.5% | +30.6% | +35.2% | +71.2% | +18.3% | +27.5% | +18.7% | +34.4% | +44.6% | |
| P/B Ratio | 66.65 | 28.75 | 38.23 | 46.94 | 48.85 | 55.99 | 60.04 | 54.52 | 48.51 | 45.09 | 39.93 | 28.86 | 32.26 |
| — | -48.6% | -36.3% | -13.9% | +0.7% | +24.2% | +50.4% | +88.9% | +50.4% | +56.9% | +18.1% | +0.3% | +12.1% | |
| P/FCF | 2273.08 | 19.91 | 136.67 | — | 239.90 | — | 3228.09 | 978.19 | — | — | — | 98.54 | 84.86 |
| — | — | -95.8% | — | — | — | — | +892.7% | — | — | — | +137.7% | +127.1% | |
| EV / EBITDA | 50.45 | 20.28 | 24.26 | 33.18 | 28.95 | 41.34 | 43.68 | 57.94 | 38.35 | 33.38 | 42.64 | 41.08 | 35.02 |
| — | -50.9% | -44.5% | -42.7% | -24.5% | +23.8% | +2.4% | +41.0% | +9.5% | +4.9% | +16.3% | +77.9% | +47.8% | |
| EV / EBIT | 55.54 | 24.23 | 26.26 | 52.65 | 34.56 | 116.43 | 57.04 | 66.91 | 51.88 | 239.08 | 52.20 | 52.27 | 41.48 |
| — | -79.2% | -54.0% | -21.3% | -33.4% | -51.3% | +9.3% | +28.0% | +25.1% | +415.5% | -20.3% | +56.2% | +15.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Eli Lilly and Company's operating margin was 47.6% in Q3 2025, up 1.8 pp QoQ and up 7.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 44.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.3% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | 80.4% | 78.3% | 76.6% | 78.8% |
| — | +2.3% | +4.3% | +2.0% | +1.7% | +0.8% | +3.3% | +5.6% | +2.6% | +4.1% | +0.4% | +4.3% | +6.0% | |
| Operating Margin | 38.9% | 47.6% | 45.8% | 42.5% | 42.8% | 39.8% | 39.1% | 31.2% | 34.1% | 37.3% | 28.1% | 24.6% | 30.2% |
| — | +19.8% | +17.2% | +36.2% | +25.5% | +6.7% | +39.0% | +26.6% | +12.9% | +27.0% | +4.6% | -27.7% | -2.1% | |
| Net Margin | 23.5% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% | 23.4% | -0.6% | 21.2% | 19.3% | 26.5% |
| — | +273.9% | +38.6% | -15.3% | +39.2% | +1503.7% | +23.7% | +32.4% | -11.8% | -102.9% | +44.5% | -20.7% | +23.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 84.3% | 26.5% | 33.1% | 18.3% | 30.8% | 6.9% | 22.4% | 18.9% | 19.8% | -0.5% | 15.7% | 12.2% | 18.5% |
| — | +281.1% | +48.0% | -2.9% | +56.2% | +1457.9% | +42.3% | +54.9% | +6.7% | -103.3% | +49.5% | -40.4% | -8.3% | |
| ROA | 14.8% | 5.2% | 5.9% | 3.3% | 5.7% | 1.3% | 4.4% | 3.5% | 3.6% | -0.1% | 3.3% | 2.6% | 4.0% |
| — | +293.1% | +36.2% | -6.4% | +59.1% | +1392.5% | +33.8% | +33.8% | -10.1% | -103.3% | +61.1% | -34.1% | +12.3% | |
| ROIC | 33.7% | 11.3% | 10.1% | 8.5% | 10.0% | 8.4% | 8.7% | 5.9% | 7.7% | 9.4% | 6.5% | 5.0% | 6.8% |
| — | +34.6% | +15.4% | +44.1% | +30.6% | -11.0% | +34.1% | +17.7% | +12.2% | +42.7% | +15.3% | -42.9% | -19.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Eli Lilly and Company's Debt/EBITDA ratio is 4.8x, down from 5.2x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 21.5% YoY to 1.55x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.36 | 1.78 | 2.17 | 2.43 | 2.36 | 2.17 | 2.12 | 2.03 | 2.32 | 1.78 | 1.69 | 1.67 | 1.51 |
| — | -18.0% | +2.6% | +19.6% | +1.5% | +21.8% | +25.5% | +21.6% | +54.1% | +14.1% | -13.1% | -4.2% | -18.3% | |
| Debt / EBITDA | 1.75 | 4.80 | 5.25 | 6.56 | 5.36 | 6.20 | 5.98 | 8.36 | 7.04 | 5.10 | 6.96 | 9.09 | 6.29 |
| — | -22.6% | -12.2% | -21.5% | -24.0% | +21.6% | -14.1% | -8.1% | +12.0% | -22.9% | -13.4% | +70.7% | +8.6% | |
| Current Ratio | 1.15 | 1.55 | 1.28 | 1.37 | 1.15 | 1.27 | 1.11 | 1.35 | 0.94 | 1.05 | 1.13 | 1.30 | 1.05 |
| — | +21.5% | +14.7% | +1.3% | +22.4% | +21.7% | -1.2% | +4.2% | -10.4% | -7.2% | +2.9% | +2.6% | -14.2% | |
| Quick Ratio | 0.89 | 1.24 | 1.00 | 1.06 | 0.89 | 0.97 | 0.87 | 1.03 | 0.73 | 0.82 | 0.87 | 1.02 | 0.80 |
| — | +28.0% | +13.8% | +3.5% | +21.2% | +18.0% | +0.1% | +1.0% | -8.7% | -6.7% | +3.3% | +4.0% | -17.2% | |
| Interest Coverage | 22.42 | 46.69 | 28.62 | 22.19 | 25.80 | 23.61 | 24.07 | 15.23 | 23.10 | 28.42 | 19.44 | 16.68 | 26.28 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonEli Lilly and Company's current P/E is 89.9x. The average P/E over the last 4 quarters is 42.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Eli Lilly and Company's current operating margin is 38.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Eli Lilly and Company's business trajectory between earnings reports.